Overview

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

Status:
Terminated

Trial end date:
2020-12-15

Target enrollment:

Participant gender:

Summary

The investigators' central hypothesis is that in patients with atrial fibrillation, anticoagulation with Apixaban reduces the rate of decline in cognitive function, when compared to Warfarin. The investigators also hypothesize that Apixaban reduces cognitive decline by reducing the rate of new cerebral infarction and cerebral microbleeds detected by cerebral MRI compared to warfarin.

Phase:

Phase 3

Details

Lead Sponsor:

Mayo Clinic

Collaborators:

Bristol-Myers Squibb
Pfizer

Treatments:

Apixaban
Warfarin